)
Visual
test
GenSight Biologics
GenSight Biologics (SIGHT) investor relations material
GenSight Biologics Q4 2025 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 TU earnings summary8 Jan, 2026
Executive summary
Cash and cash equivalents reached €2.4 million as of December 31, 2025, increasing from €0.6 million at the end of September due to a partial capital increase.
Additional €2.9 million fundraising closed on January 7, 2026, with €0.7 million used to repay convertible bonds.
Net working capital is sufficient to meet obligations through February 2026, with expected revenues from early access programs to support operations through the year.
Financial highlights
Cash position improved to €2.4 million at year-end 2025, up from €0.6 million at September 30, 2025.
After fundraising and bond repayment, cash and cash equivalents totaled €2.9 million as of January 7, 2026.
Outlook and guidance
Revenues from compassionate access programs in France and Israel are expected to ensure operational continuity through 2026.
Ongoing funding operations, both dilutive and non-dilutive, are planned to extend the cash runway and finance the RECOVER Phase III trial.
RECOVER Phase III funding strategy
Impact of Q1 2026 engineering run
EAP revenue's role in 2026 continuity
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from GenSight Biologics
- Cash position strengthened by fundraising, but runway depends on regulatory outcomes.SIGHT
Q3 2025 TU7 Oct 2025 - Net loss widened to €7.0M amid falling cash and ongoing going concern risks.SIGHTH1 202529 Sep 2025
- Cash position extended to October 2025; key regulatory and manufacturing milestones achieved.SIGHTQ2 2025 TU8 Jul 2025
- Cash burn halved and cash runway extended, pending AAC program restart in late 2024.SIGHTH1 202413 Jun 2025
- Cash runway at risk; LUMEVOQ® ready for patients pending AAC and urgent bridge financing.SIGHTQ3 2024 TU13 Jun 2025
- €6.9M cash and LUMEVOQ® vials position GenSight for AAC program resumption in late Q3 2024.SIGHTQ2 2024 TU13 Jun 2025
- Reduced net loss in 2024, but urgent funding and AAC program resumption are critical.SIGHTH2 20246 Jun 2025
- Cash runway extends only to early June 2025, with urgent fundraising now critical.SIGHTQ1 2025 TU6 Jun 2025
- Cash runway extended to February 2025 as LUMEVOQ® regulatory review and trial prep continue.SIGHTQ4 2024 TU5 Jun 2025
Next GenSight Biologics earnings date
H2 202526 Mar, 2026
GenSight Biologics
Next GenSight Biologics earnings date
H2 202526 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage